Virtus ETF Advisers’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-20,502
Closed -$117K – 541
2026
Q2
$117K Buy
20,502
+502
+3% +$2.28K 0.04% 352
2026
Q1
$90K Hold
20,000
– – 0.04% 343
2025
Q4
$123K Buy
+20,000
New +$145K 0.06% 312

Other funds holding MYGN

Virtus ETF Advisers's MYGN Position: Q3 2026 in Review

Virtus ETF Advisers sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 20,502 shares — an estimated $117K sold.

Virtus ETF Advisers first reported a position in MYGN in Q4 2025 and held it in 3 quarters. The position peaked at $123K in Q4 2025. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • Virtus ETF Advisers reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
  • Virtus ETF Advisers sold 20,502 Myriad Genetics shares in Q3 2026, an estimated $117K.
  • Virtus ETF Advisers first reported a position in Myriad Genetics in Q4 2025 and held it in 3 quarters.
  • Virtus ETF Advisers's Myriad Genetics position peaked at $123K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Virtus ETF Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.